NDATOPICALCREAM
Approved
Feb 1997
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Drug data last refreshed 26m ago · AI intelligence enriched 26m ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PANDEL is a topical corticosteroid cream containing hydrocortisone probutate, approved in 1997 for inflammatory and pruritic dermatological conditions. It is a potent mid-strength topical corticosteroid used to reduce inflammation and itching in various skin disorders. The drug works through glucocorticoid receptor binding to suppress local inflammatory responses in the skin.
$0.04MPart D
LOE ApproachingWith LOE approaching and minimal Part D engagement (33 claims, $40K spending), this product is in mature/declining phase with a likely small and specialized commercial team.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
No current job openings linked to PANDEL indicate limited active hiring, consistent with a mature product in LOE phase. Roles on this product are primarily focused on maintaining market presence and managing decline rather than growth or innovation.
Regional/Field SalesBrand Manager
Worked on PANDEL at ANI Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.